Featured Research

from universities, journals, and other organizations

Use of anti-fungal drug for premature infants clarified

Date:
May 4, 2014
Source:
Duke Medicine
Summary:
In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings of a new study. The research clarifies a choice faced by doctors treating the tiniest of newborns whose fragile immune systems are vulnerable to Candida infections: Routinely administer anti-fungal medicine to babies weighing less than 2 pounds regardless of whether they have an infection; or hold off using the drugs until an infection occurs.

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team.

The research clarifies a choice faced by doctors treating the tiniest of newborns whose fragile immune systems are vulnerable to Candida infections: Routinely administer anti-fungal medicine to babies weighing less than 2 pounds regardless of whether they have an infection; or hold off using the drugs until an infection occurs.

Studying these patients to determine the best approach has been difficult, and previous studies had limitations. The current research -- part of the Pediatric Trials Network initiative led by the Duke Clinical Research Institute -- now provides a strong scientific basis to guide neonatal doctors facing a common treatment decision.

"There has been some controversy about whether to use the drug fluconazole as a routine preventive for candidiasis," said lead author Daniel K. Benjamin Jr., M.D., Ph.D., professor of pediatrics at Duke. "Previous studies found a benefit, but they looked at reducing infections at centers with high rates of disease. Most neonatal intensive care units in the United States and Europe have low rates of disease, so questions have remained about whether the risks of using the drug among these babies are justified."

Benjamin said at most, a third of neonatal units in the United States routinely give fluconazole to extremely premature infants, which are those born earlier than 32 weeks gestation. But the question lingers about using the drug as a preventive, given potential side effects.

Publishing in the May 7, 2014, issue of the Journal of the American Medical Association, Benjamin and colleagues reported that the use of fluconazole did not significantly reduce the combined risk of death or invasive candidiasis, a lethal fungal infection that kills or impairs nearly 70 percent of the extremely premature babies it strikes.

The finding was based on a randomized, prospective study involving 32 U.S. neonatal intensive care units. Researchers enrolled 361 extremely premature infants, randomizing roughly half to receive fluconazole twice weekly for 42 days, and the other half to get a placebo.

While fewer infants who received fluconazole developed candidiasis, the death rate between the two groups was the same -- 14 percent -- leading to a composite finding that the drug did not provide a statistically significant benefit for infants treated at centers with a low incidence of infection.

"It's important to stress that using the drug to prevent the spread of infection in units with moderate to high rates of disease should continue, based on our findings," said senior author P. Brian Smith, M.D., MPH, MHS, associate professor of pediatrics at Duke. "But most babies should not be routinely put on the drug prophylactically."

Smith added that the researchers found no long-term neurological problems associated with using fluconazole, which had been a concern of doctors. With two years of follow-up, the research team found no difference in neurological outcomes between infants who took the preventive medicine and those receiving placebo.

Benjamin said the study's findings fill in missing information that doctors have needed to guide care for children -- a key goal of the Pediatric Trials Network that was established in 2010 with a $95 million, seven-year investment by the National Institutes of Health to determine the best drug choices and dosages for children.

The Duke Clinical Research Institute was selected to lead the network. Since that time, dozens of multi-institutional studies have been launched, and findings are now being published.

"We are plugging away at this bit-by-bit to determine the proper way to treat children," said Benjamin, who is principal investigator of the network. "We are turning the crank on all sorts of things that will make the lives of children better."


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Daniel K. Benjamin, Mark L. Hudak, Shahnaz Duara, David A. Randolph, Margarita Bidegain, Gratias T. Mundakel, Girija Natarajan, David J. Burchfield, Robert D. White, Karen E. Shattuck, Natalie Neu, Catherine M. Bendel, M. Roger Kim, Neil N. Finer, Dan L. Stewart, Antonio C. Arrieta, Kelly C. Wade, David A. Kaufman, Paolo Manzoni, Kristi O. Prather, Daniela Testoni, Katherine Y. Berezny, P. Brian Smith. Effect of Fluconazole Prophylaxis on Candidiasis and Mortality in Premature Infants. JAMA, 2014; 311 (17): 1742 DOI: 10.1001/jama.2014.2624

Cite This Page:

Duke Medicine. "Use of anti-fungal drug for premature infants clarified." ScienceDaily. ScienceDaily, 4 May 2014. <www.sciencedaily.com/releases/2014/05/140504095236.htm>.
Duke Medicine. (2014, May 4). Use of anti-fungal drug for premature infants clarified. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2014/05/140504095236.htm
Duke Medicine. "Use of anti-fungal drug for premature infants clarified." ScienceDaily. www.sciencedaily.com/releases/2014/05/140504095236.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins